Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

October

17

Exagen Announces Appointment of John Aballi as CEO

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN) announced today that the company has...

14

electroCore Provides Select Third Quarter 2022 Financial Guidance

ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage...

12

ATEC Launches Expandable Technology for Medialized Posterior Procedure

CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to...

11

ATEC Advances Lateral Sophistication

Innovation designed to expand lateral adoption and improve patient outcomes CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings,...

10

ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance

Total revenue of $89 to $90 million Total revenue growth of 42-43%, including organic...

4

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

Dr. Concoff to lead rheumatoid arthritis medical initiatives SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) —...

28

ATEC Advances Clinical Predictability with Procedural Solutions to be Featured at NASS 2022

Company will showcase lateral sophistication and information-based clinical influence CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc....

21

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents

Four patents issued expanding claims related to delivery of nVNS and other therapies using...

12

Neurolens Raises $67 Million from MVM Partners, Falcon Vision/KKR, Marshall Wace & Existing Investors

Investment will be used to develop new products and drive adoption DALLAS, Texas, September 12,...

7

gammaCore Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder

(Non-Invasive Vagus Nerve Stimulation; nVNS) ROCKAWAY, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR),...

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

29

Neurolens Top 30 Healthcare Company on Inc. 5000 2022 List

28th fastest-growing healthcare company on 2022 list Ranked #1,773 overall among America’s fastest-growing private...

Recent developments

October

17

Exagen Announces Appointment of John Aballi as CEO

October

14

electroCore Provides Select Third Quarter 2022 Financial Guidance

October

12

ATEC Launches Expandable Technology for Medialized Posterior Procedure

October

11

ATEC Advances Lateral Sophistication

October

10

ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance

October

4

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

September

28

ATEC Advances Clinical Predictability with Procedural Solutions to be Featured at NASS 2022

September

21

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents

September

12

Neurolens Raises $67 Million from MVM Partners, Falcon Vision/KKR, Marshall Wace & Existing Investors

September

7

gammaCore Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder

September

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

August

29

Neurolens Top 30 Healthcare Company on Inc. 5000 2022 List